.Pharmacolibrary.Drugs.ATC.L.L01EX24 .Pharmacolibrary.Drugs.ATC.L.L01EX24| name: | Surufatinib | |
| ATC code: | L01EX24 | route: | oral |
| compartments: | 2 | |
| dosage: | 300 | mg |
| volume of distribution: | 54.4 | L |
| clearance: | 9.98 | L/h |
| other parameters in model implementation | ||
Surufatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF-1R. It is developed for the treatment of neuroendocrine tumors (NETs) and has received approval in China for the treatment of non-pancreatic neuroendocrine tumors.
Pharmacokinetics reported for adult patients with advanced solid tumors, typically Asian (Chinese) individuals. Data most extensively reported for the oral administration of surufatinib at steady state.